Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Bexon Clinical Consulting (United States) | Researchclopedia

Back to institutions

Bexon Clinical Consulting (United States)

Upper Montclair, New Jerseycompany

68

Works

3,786

Citations

15

h-index

Top Research Topics

Estrogen and related hormone effects Immunotherapy and Immune Responses Cancer Immunotherapy and Biomarkers

Top Researchers

Martin Bexon Bexon Clinical Consulting (United States)

75 works3,427 citationsh-index: 13

Recent Research

CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3‐Mediated Neuroinflammation in Neurodegenerative Disease: A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics.

Louise Dickson,Roberto Tolando,et al.

20250 citations

CAR-T cell therapy research

Immune Cell Function and Interaction

Cancer Research and Treatments

Virus-based gene therapy research

SARS-CoV-2 and COVID-19 Research

Immune cells in cancer

Advanced Breast Cancer Therapies

Prostate Cancer Treatment and Research

Ovarian cancer diagnosis and treatment

Damien M. Cronier Bexon Clinical Consulting (United States)

91 works2,764 citationsh-index: 18

Mark S. Hixon Johnson & Johnson (Israel)

115 works2,119 citationsh-index: 29

Robert G. Michel Rancho BioSciences (United States)

159 works1,858 citationsh-index: 24

60 works1,768 citationsh-index: 22

Alice Bexon Rancho BioSciences (United States)

87 works911 citationsh-index: 13

Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Uğur Şahin,Alexander Muik,et al.

20251 citations

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors

Mohammed Milhem,Trisha M. Wise‐Draper,et al.

20254 citations

A phase 2 study to confirm safety and efficacy of MB-105, an autologous CD5-directed CAR T-cell therapy, in relapsed/refractory T-cell lymphoma (R/R TCL).

Swaminathan P. Iyer,Steven M. Horwitz,et al.

20250 citations

Phase 2 expansions of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2) ± cemiplimab in patients with advanced solid tumors.

Mohamad A. Salkeni,David Sommerhalder,et al.

20250 citations

Safety and efficacy of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), ± cemiplimab in patients with advanced solid tumors from a phase 1 study.

Shiraj Sen,Andrae Lavon Vandross,et al.

20252 citations